Full Press Release Details
A Letter from Amro Albanna
I am proud of our accomplishments since the completion of our IPO in
July 2020. Guided by our mission is to improve the health of the immune system, we are developing innovations in two key areas. Immune
Monitoring and Immune Retraining.
The two significant milestones that we set for Aditxt this year, 2021,
are transitioning the company from pre-revenue to revenue and transitioning our therapeutic program from pre-clinical to clinical. Revenue
growth will be driven by our immune monitoring segment, which is branded AditxtScore . Our clinical expansion will be driven through
our Aditxt Reprogramming and therapeutic segment. The following is a review of the actions we've taken towards those stated goals.
Let's start with immune monitoring. It is now more apparent than
ever, given the challenge the world has faced with the COVID-19 pandemic, that we must understand immunity status at an individual level,
not only at a population level. We have been developing AditxtScore as an immune monitoring service with a vision to transform reactive
testing into proactive monitoring. Since the IPO, we've made the following progress towards commercializing AditxtScore from a promising
innovation into a commercial product:
As we recently announced in a joint press conference with the Governor
of Virginia and the Mayor of Richmond, we are in the process of establishing our first high-capacity AditxtScore Center with a targeted
annual capacity of 10M AditxtScores per year by the end of 2023. This facility will be up and running on July 1st.
The steps above have gotten us significantly closer to our first goal
of making AditxtScore commercially available.
Now let me address our second segment, Aditxt Reprogramming which is
the therapeutics side of our business. We are developing a new class of therapeutics designed to retrain the immune system to potentially
address organ rejection, autoimmune diseases, and allergies.
Our first therapeutic technology platform is referred to as ADi, which
stands for Apoptotic DNA Immunotherapy. We've taken the following steps towards getting ADi into clinical trials, which is our second
To recap, in just 10 months since our IPO, we have expanded our IP
portfolio, recruited key team members, built the necessary infrastructure to advance development and deployment for AditxtScore and AditxtReprogramming,
and positioned the company for the commercialization of AditxtScore and clinical trials for AditxtReprogramming -- all in just 300 calendar
I hope this brief update provided a clear roadmap of our goals and
significant progress to date. I believe in Aditxt and its team, and I am tremendously excited about our prospects. We are well-positioned
to deliver innovations that could potentially address significant health challenges. Our current market cap hovers around $30M-40M depending
on the day. I know we would all enjoy a much higher market cap, but our focus is on building the company and its market share, as I believe
that will ultimately drive the value of Aditxt.
We are here today because of the many stakeholders who believed in
us and our mission. I want to take this opportunity to thank you as our shareholders. I would also like to recognize and thank our team
and our partners who have been working practically seven days a week to pursue our mission and reach the goals we set for Aditxt.
Co-Founder and Chief Executive Officer